尼沃卢马布加上伊皮利穆马布治疗肝细胞癌:改变游戏规则?
Lorenza Di Marco1, Federica Valerio1, Yuri Maculan1
1Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Italy.
Expert opinion on biological therapy
|March 5, 2026
概括
尼沃卢马布和伊皮利穆马布的双重免疫检查点抑制显示了晚期肝细胞癌 (HCC) 的生存益处. 这种免疫疗法为选定的患者提供了一种新的一线选择,尽管可能存在与免疫相关的毒性.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 在瘤学中的免疫疗法.
- 肝脏疾病和癌症免疫学
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因,通常与慢性肝病和肝硬化有关.
- 在HCC中,免疫抑制性瘤微环境需要优化免疫治疗策略,以改善患者的治疗结果.
- 了解肝硬化和HCC进展中的免疫耐受机制至关重要.
研究的目的:
- 审查高级HCC中双重免疫检查点抑制 (nivolumab加上 ipilimumab) 的生物基础和临床数据.
- 分析肝病和HCC中免疫耐受性的机制,包括T调节细胞,MDSC,缺氧和T细胞耗尽.
- 评估CheckMate 040和CheckMate 9DW等研究的临床证据,将结果与氨酸激酶抑制剂进行比较.
主要方法:
- 在PubMed,Embase和瘤学大会会议记录中进行结构化的文献搜索.
- 对HCC中双重免疫检查点阻塞的临床前和临床研究的分析.
- 检查临床试验数据,重点关注整体存活率,反应率和耐久性.
主要成果:
- 使用尼沃卢马布加上伊皮利穆马布的双重检查点阻塞是选择高级HCC患者的有效一线治疗方法.
- 与传统治疗相比,这种组合疗法显示出有意义的生存益处.
- 增加与免疫相关的毒性与双重检查点封锁有关.
结论:
- 双免疫检查点抑制为先进的HCC提供了一个有希望的第一线治疗策略.
- 未来的进展依赖于增强的患者选择,生物标志物发现和组合疗法.
- 与免疫相关的毒性平衡疗效是优化治疗结果的关键.
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
670
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
670


